Term: 06/21 - 05/26 (5 years)
Partner: Department of Ophthalmology and Optometry, Medical University of Vienna
Lab for Ophthalmic Image Analysis, Medical University of Vienna
Funding: FWF (Research Groups programme)
Any disease of the retina at the back of the eye directly impacts visual performance and readily puts vision at risk often leading to practical blindness. For this reason, we need better understanding of retinal disease and their progression patterns to find good retinal treatment solutions. Personalized medicine is an emerging approach where medical decisions and therapies are being tailored to the individual patient.
Today, innovations in medical imaging allow an extraordinarily detailed view into one's health condition. The introduction of optical coherence tomography (OCT) imaging provides a view of the retina in three-dimensions and in very fine detail. The analysis of the sheer volume of information about patients, disease progression and OCT images even exceeds the human capabilities.
In the last decade, artificial intelligence (AI) has revolutionized various fields of science in an unprecedented manner. There is relentless pressure and expectation to deploy AI in medicine, especially in image-intensive branches. In Ophthalmology, it has already achieved super‑human performance in image diagnosis. Nevertheless, despite initial successes, most of AI’s enormous potential is still to be realized, and in ophthalmology it remains heavily under‑exploited.
This Research Group has an overarching goal to identify populations of similar retinal patients and build clinical decision support tools to improve treatment of an individual patient. We focus on developing, improving and applying AI methods to analyze OCT images of retina and we investigate machine learning methods that can provide individual prognosis of disease advance. The Group is composed of four world-class and pioneering researchers from the Medical University of Vienna (Ursula Schmidt-Erfurth and Hrvoje Bogunović) with expertise in ophthalmology and medical imaging, and the Johannes Kepler University (Sepp Hochreiter and Günter Klambauer) with expertise in AI. They are joining their complimentary expertise with the goal of introducing AI-based personalized medicine into the management of the leading eye diseases of modern times.